Hlib Chabaniuk

Atossa Therapeutics posts trial data showing reduced breast density in premenopausal women

Atossa Therapeutics posts trial data showing reduced breast density in premenopausal women
Atossa reports reduced breast density

Atossa Therapeutics, Inc. announced the publication of pivotal results from its KARISMA-Endoxifen trial, reporting significant reductions in mammographic breast density among healthy premenopausal women.

The findings bolster the case for the continued development of (Z)-endoxifen as a preventive option for breast cancer. Atossa Therapeutics is advancing its research towards addressing unmet needs in breast cancer prevention, signaling a potentially important development in women’s health.

Atossa previously advanced Z-endoxifen in oncology with new U.S. FDA designations and changes in clinical leadership, according to a recent update. The company has also discussed endoxifen as a novel approach for Duchenne muscular dystrophy in a podcast presentation. These developments reflect the company’s expanding pipeline across therapeutic areas.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.